Amacathera

AmacaThera is a clinical-stage biotechnology company transforming therapeutics through its proprietary injectable hydrogel platform, which blends hyaluronic acid and methylcellulose to enable localized, sustained release of small molecules, biologics, enzymes, and cells. The platform's tunability allows fine adjustment of drug release rate, duration, and timing for each clinical application. AmacaThera's lead program, AMT-143, is a long-acting non-opioid anesthetic for post-operative pain management, developed under a $230M global licensing agreement with Pacira BioSciences.